Did you know that 1 in 8 men will develop prostate cancer in their lifetime? While most cases are not fatal, prostate cancer does kill ~34,000 Americans every year. For researchers dedicated to advancing treatment for patients with prostate cancer, Truveta provides the most complete, timely, and clean regulatory-grade EHR data for scientifically rigorous research. Truveta Data also includes data from both urology clinics and the rest of the EHR, including oncology data, which is particularly important for prostate cancer research, since most cases are first treated by urologists. Learn more about the prostate cancer data we have available for research: https://tr.vet/4aAWq6N #ProstateCancer #ProstateCancerResearch #CancerResearch #CancerData #HealthData #HealthResearch #HealthcareData #HealthcareResearch #HealthAI #HealthcareAI #MedicalResearch #MedicalData #MedicalAI #MedicalInnovation #EHRData #ElectronicHealthRecords #UrologyData #UrologyClinic #OncologyResearch #OncologyData #AI #Innovation
Truveta
Hospitals and Health Care
Seattle area, Washington 67,519 followers
Saving Lives with Data
About us
Truveta is a growing collective of more than 30 health systems, who provide over 18% of the daily clinical care across the United States, with a shared mission of Saving Lives with Data. Trusted by more than 50 leading life science, government, and healthcare organizations, Truveta enables scientifically rigorous research with regulatory-grade data and powerful analytics.
- Website
-
http://www.truveta.com
External link for Truveta
- Industry
- Hospitals and Health Care
- Company size
- 201-500 employees
- Headquarters
- Seattle area, Washington
- Type
- Privately Held
- Founded
- 2020
- Specialties
- Technology, Artificial Intelligence, Health, Data, Health Equity, RWE, RWD, Healthcare Data, and Large Language Model
Locations
-
Primary
Seattle area, Washington, US
Employees at Truveta
Updates
-
Via CNN: "People taking tirzepatide injections lost more weight and were more likely to reach specific weight loss targets than those taking semaglutide, according to a new study. Researchers from Truveta, a health data analytics company, analyzed electronic health records for more than 18,000 adults, all of whom had overweight or obesity, who were using these medications in the real world between May 2022 and September 2023. The findings were published ... in the JAMA Internal Medicine medical journal." Read more from CNN Health Data Editor Deidre McPhillips: https://tr.vet/4f1Evtj #tirzepatide #semaglutide #Mounjaro #Ozempic #WeightLoss #WeightLossMedication #WeightLossDrugs #PrescriptionTrends #GLP1s #HealthData #HealthcareData #HealthcareAI #HealthAI #AI #Innovation #HealthInnovation #HealthcareInnovation #MedicalData #MedicalAI #MedicalInnovation #MedicalTechnology #MedTech #EHRData #ElectronicHealthRecords
-
This week in USA TODAY: ""As we've tracked GLP-1 use over the last couple of years, we've just seen these dramatic increases of use," said Tricia Rodriguez, who led the study for Truveta Research, and both drugs are "really revolutionizing the treatment of both diabetes and obesity."" Learn more about our GLP-1 comparative effectiveness study, which was recently published in JAMA Internal Medicine: https://tr.vet/4czuwKl #GLP1 #Semaglutide #Tirzepatide #WeightLoss #WeightLossDrugs #PeerReviewed #JAMA #ResearchPublication #HealthData #HealthTech #HealthcareData #HealthcareTech #PrescriptionTrends #PrescriptionData #MedicalData #MedicalTechnology #MedTech #JAMAInternalMedicine #RealWorldData #RealWorldEvidence #AI #HealthAI #HealthcareAI #MedicalAI #Innovation #HealthInnovation #HealthcareInnovation #MedicalInnovation
Ozempic v. Mounjaro? There's a clear winner for weight loss, study finds.
usatoday.com
-
This week, we had the great honor of hosting a selection of our customers and members from across healthcare, life sciences, and public health at our second annual Truveta Symposium. Catch some highlights from the event in the video below! Huge thank you to all those who joined us in the Seattle area this week. We're leaving Symposium inspired by the creativity and passion our partners are pouring into our shared mission of Saving Lives with Data - and we're already looking forward to next year.
-
It's almost time for our annual Truveta Symposium! We're excited to connect with our customers and members this week, as we work together towards our shared mission of Saving Lives with Data. Learn more about the event, and check out a selection of our sessions and presenters for this week: https://tr.vet/3S1fjZY
Truveta Symposium 2024
truveta.com
-
This week, we're thrilled to welcome a collection of our life science and health system customers and members for our second annual Truveta Symposium. This event is dedicated to bringing together leaders from across health systems, life sciences, academic research, and government organizations, with goals to: 🤝 Collaborate on ways to advance innovative research with real-world data 🙌 Embrace generative AI to transform healthcare 🧑⚕️ Improve patient care and outcomes for all This video from our inaugural Truveta Symposium in 2023 shows the energy and passion of our partners for our shared mission of Saving Lives with Data. We're so excited to see what's to come this week! Learn more about Truveta Symposium: https://tr.vet/4cW0HDd #HealthSystems #LifeSciences #MedicalResearch #HealthResearch #HealthcareResearch #HealthData #MedicalData #HealthcareData #HealthcareConference #HealthConference
-
Via the Los Angeles Times: "In the first head-to-head comparison of two blockbuster drugs used in real-world conditions, people who took Mounjaro lost significantly more weight than their counterparts who took Ozempic — and the longer the patients kept taking the drugs, the wider the gap became." Read the LA Times' coverage of our comparative effectiveness study that was recently published in JAMA Internal Medicine: https://tr.vet/4cSIAhs #ComparativeEffectiveness #Mounjaro #Ozempic #Semaglutide #Tirzepatide #WeightLossDrugs #WeightLoss #HealthData #HealthTech #HealthAI #HealthcareAI #HealthInnovation #HealthcareInnovation #Innovation #AI #HealthData #HealthcareData #PrescriptionTrends #PrescriptionData #MedicalData #MedicalTechnology #MedTech
Mounjaro bests Ozempic for weight loss in first head-to-head comparison of real-world use
latimes.com
-
Now available via JAMA Internal Medicine: Truveta Research's study using real-world data on weight loss trends among patients with overweight or obesity taking tirzepatide (Mounjaro) versus semaglutide (Ozempic) found that those taking tirzepatide were 3.2x more likely than their counterparts taking semaglutide to achieve 15% weight loss. This is the largest comparative effectiveness study of its kind, and it's now peer-reviewed. Learn more: https://tr.vet/3XVCPeS #JAMA #JAMAInternalMedicine #PeerReviewed #MedicalJournal #Semaglutide #Tirzepatide #Ozempic #Mounjaro #WeightLossDrugs #WeightLoss #WeightLossTrend #BMI #ComparativeEffectiveness #HealthData #HealthcareData #HealthcareTrends #HealthTrends #HealthAI #HealthInnovation #AI #Innovation #MedicalData #PrescriptionTrends #PrescriptionData #MedicalTechnology #MedTech
Study comparing Mounjaro and Ozempic published in JAMA Internal Medicine
truveta.com
-
Recently, Truveta Research released the latest installment of their GLP-1 RA monitoring report. The report shows that overall prescription rates and first-time prescriptions for medications that are now commonly being prescribed for weight loss, like semaglutide, tirzepatide, and others, aren't showing any signs of slowing down. Use your LinkedIn credentials to view the report in Truveta Studio: https://tr.vet/4eC6IXD #Semaglutide #Tirzepatide #Liraglutide #GLP1 #GLP1Data #GLP1PrescriptionTrends #PrescriptionTrends #PrescriptionData #HealthData #HealthTech #HealthcareData #HealthcareAI #HealthcareInnovation #AI #Innovation #LLM #MedicalResearch #MedicalTechnology #MedTech #WeightLoss #WeightLossDrugs
Truveta Studio: GLP-1 RA prescription trends monitoring report
login.truveta.com
-
Truveta offers regulatory and audit capabilities to support customers in real-world evidence submissions to the FDA and other global regulatory authorities. RWE can clearly demonstrate real-life clinical performance, so we've invested in establishing: ✅rigorous standards of data quality and provenance, 📃workflow support for regulatory submissions, and 🔎audit-ready processes and controls to support life science orgs in meeting the most stringent regulatory requirements. Learn more: https://tr.vet/3Rx4qiG #RWE #RealWorldEvidence #RegulatoryGrade #RegulatorySubmission #FDA #FoodAndDrugAdministration #DataQuality #RealWorldData #RWD #HEOR #ClinicalTrials #LifeSciences #RegGrade
Truveta supports regulatory submissions to the FDA
truveta.com